What is Eccogene?
Eccogene operates as a specialized biopharmaceutical developer dedicated to the discovery and advancement of best-in-class small molecule drugs. The company distinguishes itself through a robust pipeline that targets complex metabolic pathways, including THR-β and SSAO. By prioritizing oral therapies that can function independently or as adjuncts to GLP-1 receptor agonists, Eccogene is strategically targeting the next frontier of metabolic health. Their operational model emphasizes the creation of cost-effective, accessible treatments designed to improve patient outcomes on a global scale, moving beyond simple weight management to address the underlying systemic drivers of chronic disease.
How much funding has Eccogene raised?
Eccogene has raised a total of $25M across 1 funding round:
Series B
$25M
Series B (2023): $25M with participation from Zhangjiang Healthcare Venture Capital, Huajin Capital, Oriza Seed Capital, and New Alliance Capital
Key Investors in Eccogene
Zhangjiang Healthcare Venture Capital
A specialized investment firm focusing on the life sciences sector, providing critical backing to innovative healthcare startups in the Zhangjiang high-tech park ecosystem.
Huajin Capital
A prominent investment institution known for supporting high-growth technology and healthcare enterprises through strategic financial partnerships.
Oriza Seed Capital
An early-stage investment firm that provides essential capital and operational guidance to emerging companies within the biotechnology and pharmaceutical industries.
What's next for Eccogene?
With the successful closure of this major enterprise-level funding, Eccogene is poised to transition its clinical programs into more advanced phases of development. The strategic allocation of this capital will likely focus on scaling clinical trial operations and expanding the reach of its preclinical metabolic disease portfolio. As the company continues to refine its therapeutic candidates, the focus will remain on demonstrating superior efficacy and safety profiles compared to existing standards of care. Investors are closely monitoring the firm's ability to navigate the regulatory landscape while maintaining its trajectory toward commercialization in the competitive cardiometabolic market.
See full Eccogene company page
